Eli Lilly (LLY) led a Stocktwits poll with 32% of votes as the top obesity-drug stock for the next five years, ahead of Novo Nordisk (NVO) and Hims & Hers Health (HIMS) at 26%, and Viking Therapeutics (VKTX) at 16%. Traders cited strong pipelines and expected TrumpRx pricing deals expanding Medicare access for Zepbound and Wegovy, while Viking generated buzz.